Search

First Affiliated Hospital of Zhejiang University

National Cancer Institute (NCI)

Ruijin Hospital and Yang Li, Professor

National Cancer Institute (NCI)

Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, and Teva Pharmaceuticals Europe

Yi Han, Associate professor of pharmacy

Li Junmin, director of the hematology department

National Laboratory Astana

National Cancer Institute (NCI)

Yang Li, Professor

Min Lu, Professor, Ph.D.

David Gomez Almaguer, Head of Hematology Service

Study Alliance Leukemia (SAL) Group

National Cancer Institute (NCI)

Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences and Linghua LI, Vice Chief physician

Cephalon, Inc.

Xing Xie, profressor

Northwestern University, New York Presbyterian Hospital, University of Southern California, Princess Margaret Hospital, Canada, and National Heart, Lung, and Blood Institute (NHLBI)

Tang-Du Hospital

M.D. Anderson Cancer Center and Teva Pharmaceuticals USA

Jun Zhang, Chief of department of oncology

Cephalon, Teva Pharmaceuticals USA, National Cancer Institute (NCI), and Taofeek K. Owonikoko, Associate Professor, Hematology/Medical Oncology, Principal Investigator

Yuan-Sheng Zang, Department Director

Jean Yuh Tang, Associate Professor of Dermatology

National Cancer Institute (NCI)

National Cancer Institute (NCI)

Cephalon

CTI BioPharma and Celgene Corporation

wang, jianxiang, Director of Diagnosis and Treatment Center for Leukemia

Cephalon and CTI BioPharma

Ministry of Science and Technology of the People´s Republic of China and Xiaojun Huang,MD, Director of Hematology Department

Tang-Du Hospital, Peking University People's Hospital, First Affiliated Hospital of Zhejiang University, Tongji Hospital, Wuhan Union Hospital, China, First Hospital of China Medical University, Southwest Hospital, China, West China Hospital, Ningbo No. 1 Hospital, Qilu Hospital of Shandong University, Shandong Provincial Hospital, Union hospital of Fujian Medical University, First Affiliated Hospital of Guangxi Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Second Affiliated Hospital of Dalian Medical University, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Anhui Medical University, Institute of Hematology & Blood Diseases Hospital, China, and Jiong HU, Department of Hematology

John P. Fruehauf, Associate Clinical Professor of Medicine

National Cancer Institute (NCI)

National Institutes of Health (NIH), Teva Pharmaceuticals USA, and David Avigan, MD, Prinicipal Investigator

National Cancer Institute (NCI)